1
Clinical Trials associated with Nanobody-Based Anti-CD5 CAR-T(Hebei Senlangbio Biotechnology)A Phase I Dose-Escalation and Phase II Study of Nanobody-Based CD5-Targeted CAR-T Cells for the Treatment of Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia/Lymphoma (T-ALL/LBL) - The CONQUER Trial
To observe the safety and efficacy of Nanobody-Based CD5-targeted chimeric antigen receptor T cells in the treatment of refractory or relapsed T-ALL/LBL.
100 Clinical Results associated with Nanobody-Based Anti-CD5 CAR-T(Hebei Senlangbio Biotechnology)
100 Translational Medicine associated with Nanobody-Based Anti-CD5 CAR-T(Hebei Senlangbio Biotechnology)
100 Patents (Medical) associated with Nanobody-Based Anti-CD5 CAR-T(Hebei Senlangbio Biotechnology)
100 Deals associated with Nanobody-Based Anti-CD5 CAR-T(Hebei Senlangbio Biotechnology)